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Ghrelin, an endogenous ligand for the growth hormone secretagogue receptor, is synthesized as a preprohormone and then
proteolytically processed to yield a 28-amino acid peptide. This peptide was originally reported to induce growth hormone release;
large evidence, however, has indicated many other physiological activities of ghrelin, including regulation of food intake and
energy balance, as well as of lipid and glucose metabolism. Ghrelin receptors have been detected in the hypothalamus and the
pituitary, but also in the cardiovascular system, where ghrelin exerts beneﬁcial hemodynamic activities. Ghrelin administration
acutely improves endothelial dysfunction by increasing nitric oxide bioavailability and normalizes the altered balance between
endothelin-1 and nitric oxide within the vasculature of patients with metabolic syndrome. Other cardiovascular eﬀects of ghrelin
include improvement of left ventricular contractility and cardiac output, as well as reduction of arterial pressure and systemic
vascularresistance.Inaddition,antinﬂammatoryandantiapoptoticactionsofghrelinhavebeenreportedbothinvivoandinvitro.
This review summarizes the most recent ﬁndings on the metabolic and cardiovascular eﬀects of ghrelin through GH-dependent
and -independent mechanisms and the possible role of ghrelin as a therapeutic molecule for treating cardiovascular diseases.
1.Introduction
Ghrelin, a 28-amino-acid peptide hormone mainly secreted
by the X/A-like cells in the oxyntic mucosa of the stomach,
has been discovered as the endogenous ligand of the orphan
receptor growth hormone secretagogues 1a (GHS-R1a) [1].
In addition to its marked growth hormone (GH) releasing
activity, ghrelin stimulates food intake and is involved in
the regulation of energy homeostasis [2]. Furthermore,
ghrelin has a variety of cardiovascular activities, including
cardioprotective eﬀects against ischemia, enhancement of
vasodilation, cardiotropic eﬀects, and regulation of blood
pressure [3–5].
Human ghrelin gene is located on chromosome 3 and
consists of 4 exons and 3 introns that encode a 117-amino-
acid peptide, pre-proghrelin, that is cleaved into the mature
28-amino-acidform(3.3kDa)secretedintothebloodstream
[6, 7]. Two major forms of ghrelin are found in tissues and
plasma: n-octanoyl-modiﬁed ghrelin and des-acyl ghrelin
[7]; ghrelin is the ﬁrst known secreted bioactive peptide in
mammalsmodiﬁedbyanacylacidonitsthirdserineresidues
throughtherecentlydiscoveredenzymeghrelinO-acyltrans-
ferase (GOAT) [8–10]. This postranslational modiﬁcation is
essential for binding to the GHS-R 1a and for several ghrelin
biological activities, including the GH-releasing capacity
and the actions on the endocrine axis, on energy balance
and glucose homeostasis [3]. Nonacylated ghrelin, which
represents the most abundant form of circulating ghrelin
(80%–90%), has been found to be devoid of GH releasing
capacity [1, 11, 12] ,b u te x e r t sav a r i e t yo fp h y s i o l o g i c a l
activity in the cardiovascular system as well as in lipid and
glucose metabolism [13, 14].
Centralandperipheraladministrationofdes-acylghrelin
signiﬁcantly decreases food intake and decreases gastric
emptying in food-deprived mice [15]. In another study,
Chen et al. conﬁrmed that des-acyl ghrelin decreases food
intake in mice and showed that ghrelin disrupts the fasted
motor activity of the antrum in freely moving conscious
rats [16]. Moreover, centrally administrated des-acyl ghre-
lin increases feeding through activation of the orexin2 International Journal of Peptides
pathway and may act in hypothalamic feeding regulation
[17].
Ghrelin plasma levels are mainly regulated by nutritional
and metabolic factors; in fact they are increased by energy
restriction (such as malnutrition, anorexia nervosa, and
cachexia) and decreased by food intake and overfeeding
[18]. These notions are in agreement with several studies
showing reduced circulating ghrelin in patients with obesity
and metabolic syndrome [19, 20]. Furthermore, ghrelin
circulating levels increase in obese subjects when they lose
weight [21, 22].
While all forms of human obesity have inappropriately
low ghrelin levels, the only exception is the Prader-Willy syn-
drome, a complex genetic disorder characterized by mental
retardation, hyperphagia, short height due to GH deﬁciency,
and muscular hypotony [23]. In these patients, excessive
appetite causes progressive obesity, which is surprisingly
associated with high ghrelin levels in the same range of
patients with anorexia nervosa.
In a recent study, Kirchner et al. suggested that the
ghrelin/GOAT system acts as a lipid nutrient sensor that
informs the central nervous system on the availability of
substrates, rather than a meal initiation factor in reply
to fasting [10]. It has also been reported that ghrelin is
not inhibited by gastric distension due to water intake
but is reduced by glucose administration [24]. Moreover,
intravenous glucose loads inhibit ghrelin secretion, whereas
protein intake seems to increase or to not modify ghrelin
levels [25]. By contrast, constant infusion of lipids does not
inﬂuence ghrelin levels, while oral administration of fats
reduces them, even though not as much as glucose adminis-
tration[26].Moreover,ithasbeendemonstratedthatghrelin
induces an increase in glucose levels and this eﬀect could
be related to activation of glycogenolysis, increased liver
gluconeogenesis, or stimulation of catecholamine release
[27–30].
A negative association has been shown between ghrelin
and insulin secretion [31], but the exact mechanisms by
which insulin regulates ghrelin secretion need further stud-
ies. Hyperinsulinemia, however, has been suggested to act as
a feedback mechanism to suppress ghrelin secretion, because
several studies have reported reduced plasma ghrelin in
association with diﬀerent insulin resistance states, including
hypertension, type 2 diabetes, or polycystic ovary syndrome
[32].
A positive correlation between ghrelin and high-density
lipoprotein (HDL) cholesterol concentration has also been
observed [33, 34] and, in another study, Park et al. have
shown that fasting plasma ghrelin levels are negatively
correlated with triglycerides and positively correlated with
HDL cholesterol in boys but not in girls; the mechanism
underlying this sex diﬀerence, however, is not well estab-
lished [35].
Ghrelin secretion seems to be under cholinergic con-
trol, since ghrelin levels are raised by cholinergic agonists
and reduced by cholinergic antagonists [14]. In addition,
Williams et al. showed that fast-induced rise of ghrelin levels
is prevented by vagotomy and is reduced by atropine in rats
[36]. Interestingly, ghrelin stimulates the diﬀerentiation of
preadipocytes and antagonizes lipolysis in vitro [37]a n d
promotes bone marrow adipogenesis in vivo [38]. Chronic
ghrelin administration increases body weight, adiposity, and
the expression of uncoupling protein (UCP) mRNA in
brown and white adipose tissue in mice [39].
2. Tissue Distribution of Ghrelinand
GhrelinReceptor
Ghrelin is predominantly produced by the stomach, but
it is also widely expressed in diﬀerent tissues, such as the
hypothalamus,pituitarygland,smallandlargeintestine,pla-
centa, pancreas, kidney, testes, ovary, and lymphocytes [40].
Ghrelin has also been found in several human neoplastic
tissues and related cancer cells such as gastric and intestinal
carcinoids, lymphomas and thyroid, breast, liver, lung, and
prostate carcinomas [41, 42].
The ghrelin receptor (GHS-R) is a typical G-protein-
coupled, seven transmembrane domain receptor. The gene
of the human GHS-R 1a is located on chromosome 3q26.2
[43] and encodes for two diﬀerent splice forms of the
human GHS-R: GHS-R 1a, which binds ghrelin and leads to
intracellular calcium mobilization, and GHS-R 1b, which is
not able to bind ghrelin [44].
The GHS-R 1a is particularly concentrated in the
hypothalamic-pituitary unit but is also present in other areas
of the central nervous system and in several endocrine and
nonendocrine tissues, including pancreas, lung, liver, kidney,
small and large intestines, myocardium, spleen, ovary, testis,
adrenal, adipose tissue, stomach, and the neuronal cells of
the gut, both in animals and humans [45].
Also the GHS-R 1b has been found in many peripheral
organs,includingimmunecells,skin,myocardium,pituitary,
thyroid, pancreas, ileum, colon, liver, breast, spleen, duo-
denum, placenta, lung, adrenal, buccal mucosa, stomach,
lymphonode, atrium, lymphocytes, and kidney [46]. Inter-
estingly, both GHS-R subtypes have been found in tumoral
tissues from organs that do not express these receptors in
physiological conditions, for example, the breast [47].
In humans, the mRNA encoding GHS-R1a is detected in
the cardiovascular system, but its expression in this system
is much lower than in the pituitary [46]. Other authors
have shown that human endothelial cells express ghrelin
and the presence of ghrelin receptor has been reported in
human endothelial cells, vascular smooth muscle cells, and
the left ventricle [48]. Also GHS-R1b transcripts are highly
expressed in human myocardium, but their physiological
function is still unknown [46].
Analyzing ghrelin binding sites in the cardiovascular
system, Katugampola et al. demonstrated a higher density
of receptors in the myocardium of the right atrium than
in the left ventricle, whereas aorta and pulmonary artery
have more receptors than saphenous vein or coronary artery
(Table 1). Moreover, the same investigators noticed a change
in receptors density as a consequence of vascular diseases,
with upregulation of ghrelin in vessels with advanced
intimal thickening [49]. Binding studies have evidenced the
existence of a subtype of ghrelin receptor distinct fromInternational Journal of Peptides 3
GHS-R 1a, with the same binding aﬃnity both for acylated
ghrelin and nonacylated ghrelin, in H9C2 cardiomyocites
and endothelial cells [50].
3.CardiovascularEffectsof Ghrelin
Studies both in animal models and humans have shown
beneﬁcial eﬀects of ghrelin in the cardiovascular system to
supportthewideexpressionofitsreceptorsincardiovascular
tissues (Figure 1).
In animal models, ghrelin has been found to improve
cardiac contractility in pathological conditions, to reduce
the infarct size and to attenuate the reduction in left
ventricular function induced by ischemia-reperfusion [51].
Inparticular,Frascarellietal.havefoundthatghrelinadmin-
istration signiﬁcantly reduces the infarct size, as estimated
by triphenyltetrazolium chloride staining, in a rat ischaemia-
reperfusion model [52, 53]. Furthermore, in a group of rats
following myocardial infarction, ghrelin administration has
shown to increase body weight, cardiac output, and diastolic
thickness of the noninfarcted posterior wall, as well as to
inhibit left ventricular enlargement [53]. In animal models
of heart failure, ghrelin administration improves cardiac
contractility and attenuates the development of cardiac
cachexia [52, 53].
In normal subjects, intravenous or subcutaneous ghrelin
injection increases cardiac output, improves cardiac con-
tractility, and causes a signiﬁcant decrease in mean arterial
pressure, without changing heart rate [54]. In addition to
this, abundant evidence demonstrates a therapeutic eﬀect of
ghrelin in patients with heart failure. Thus, ghrelin has been
reported to improve left-ventricular function and to atten-
uate left-ventricular remodelling in patients with chronic
heart failure; in addition, acute ghrelin administration has
shown to decrease systemic vascular resistances and increase
cardiac output, cardiac index, and stroke volume index in
patients with chronic heart failure [55] .T h es a m ea u t h o r s
have noticed that treatment with ghrelin for three weeks
increases body weight, lean body mass, and muscle strength
[55].Theseresultssuggestthatghrelincouldimprovemuscle
wasting in patients with chronic heart failure and cardiac
cachexia, a severe catabolic state characterized by weight loss
and muscle wasting, resistant to long-term treatment with
nutritional supplements.
In keeping with these ﬁndings, other studies have
emphasized that ghrelin might have a role in patients with
end-stage heart failure and cardiac cachexia, by improving
cardiac function and increasing appetite [56, 57]. Ghrelin
intravenous administration has therefore been proposed as
adjuvant therapy in heart failure, due to its capacity to lead
to a gain in left ventricular mass, to increase left ventricular
ejection fraction, and to decrease left ventricular end-systolic
volume [55].
A negative correlation has been noticed between ghrelin
plasma levels and blood pressure, which might suggest that
ghrelin is also involved in the sympathetic regulation. In
fact, ghrelin seems to suppress sympathetic activity and
to decrease blood pressure through mechanisms involv-
ing the central nervous system [58]. This hypothesis is
supported by studies showing that ghrelin administration
signiﬁcantly decreases plasma norepinephrine levels and
the ratio between low-to-high frequency spectra of heart
rate variability in rats with myocardial infarction [59].
The reduction in peripheral resistance following ghrelin
intravenous infusion results in a decrease in blood pressure
levels in humans, even though supraphysiological hormone
levels are required to produce this eﬀect [54, 60]. Other
mechanisms have been proposed to explain the reduction
in blood pressure after ghrelin administration, including
vasodilation via endothelium activation or a direct eﬀect on
vascular smooth muscle cells [27, 61].
In vitro studies suggested that, in human mammary
artery, ghrelin causes vasorelaxation by antagonizing the
endothelin-inducedcontraction[61].Wehavedemonstrated
that ghrelin reverses endothelial dysfunction in patients
with metabolic syndrome by increasing nitric oxide (NO)
bioavailability [62]. We have also reported the molecular
vascular actions of ghrelin, which stimulates the production
of NO using a signaling pathway involving GHS-R 1a, PI
3 kinase, AKT, and eNOS [63]. More recently, we have
extended our knowledge regarding the favorable endothelial
actions of ghrelin by demonstrating that this peptide nor-
malizes the altered NO/ET-1 balance within the vasculature
of patients with metabolic syndrome, thus suggesting an
important role of ghrelin in the regulation of vascular
homeostasis [64].
4.AntiapoptoticEffectsofGhrelinin
theCardiovascularSystem
Ghrelin has also shown to act as an antiapoptotic peptide in
the cardiovascular system.
In vitro studies suggest that ghrelin stimulates H9c2 car-
diomyocyte proliferation and reduces doxorubicin-induced
apoptosis in cardiomyocytes and endothelial cells [50, 65].
Iglesias et al. found that ghrelin is synthesized and secreted
by isolated murine and human cardiomyocytes and is able to
prevent apoptosis induced by treatment with the apoptosis-
inducer cytosine arabinoside (AraC) in mouse adult cardy-
omyocites cell line HL-1 [66]. Moreover, ghrelin treatment
of primary cardiomyocytes prevents apoptosis stimulated by
anti-FAS agonist antibodies. In addition, ghrelin stimulates
tyrosine phosphorylation and activates ERK-1/2 and Akt
in cardiomyocytes and endothelial cells; the activation of
these two pathways is required for the antiapoptotic eﬀect
of ghrelin [50]. Furthermore, Isgaard et al. have found
that ghrelin is also able to stimulate proliferation of H9c2
cardiomyocytes (a cardiac cell line that does not express the
ghrelin receptor) in a dose-dependent and speciﬁc manner
by increasing thymidine incorporation; however, they have
reported the presence of alternative ghrelin binding sites on
cardiomyocytes cell membranes in the absence of GHS-R
1a [67]. In another study, Kola et al. have proposed that
ghrelin might modulate intracellular energy balance in a cell
speciﬁc manner: ghrelin would be able to stimulate the 5-
AMP activated protein kinase (AMPK) that has a central
role in regulating energy provisions in cells especially during4 International Journal of Peptides
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Figure 1: Cardiovascular eﬀects of ghrelin.
Table 1: GHS1 receptors in the human cardiovascular system.
Myocardium
Left ventricle
Aortic endothelium
Mammary artery
Coronary artery
Ventricular cardiomyocites
Vascular smooth muscle
Carotid
Saphenous vein
anaerobic conditions [68]. Ghrelin eﬀect on AMPK activity
may be involved in the mechanism of cardioprotection from
cellular injury and from ischemia-reperfusion damage [60].
5. Anti-inﬂammatory Effect of Ghrelin
Recent ﬁndings suggest that ghrelin has potent anti-
inﬂammatory eﬀects within the immune system and in
human endothelial cells.
Dixit et al. found that ghrelin exerts speciﬁc and selective
inhibitory eﬀects on the expression of the inﬂammatory
cytokines IL-1β,I L - 6 ,a n dT N F - α [69]. Moreover, T lym-
phocytes express both ghrelin and the GHS-R and ghrelin
secretionisincreasedwhenTlymphocytesareactivated[69].
Administration of the GHS.1a agonist GHRP-2 results in
decreasedIL-6levelsandreducedsignsofjointinﬂammation
in arthritic rats [70]. Moreover, DeBoer et al. reported a sig-
niﬁcant decrease in circulating proinﬂammatory cytokines
in ghrelin-treated rats with chronic kidney diseases (CKD);
they also observed an increase in the circulating levels of the
anti-inﬂammatory cytokines IL-10 in CKD rats treated with
the ghrelin receptor agonist BIM-28125 [71]. In addition,
ghrelin has potent anti-inﬂammatory eﬀects in human
endothelial cells, likely mediated by inhibition of NF-κB, and
also inhibits inﬂammatory cytokines produced by endothe-
lial cells in response to LPS [72]. These anti-inﬂammatory
eﬀects of ghrelin suggest a possible modulatory role of
the peptide as a novel strategy in several cardiometabolic
disorders associated with chronic systemic inﬂammation.
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